IRB #

IRB00010264

Title

Protocol H8A-MC-LZAZ(a)/ADC-040-A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)

Principal Investigator

Lisa Silbert

Study Purpose

The purpose of this study is to test whether an investigational drug called solanezumab, which is given by infusion through a vein, can slow the progression of memory problems associated with Alzheimer's disease.

Medical Condition(s)

Alzheimer's disease

Eligibility Criteria

In good general health, 65-85 years old, at risk for memory decline due to Alzheimer's.

Healthy Volunteers Needed

Yes

Placebo Chance

50

Duration of Participation

168 weeks

Minors Included

No

Contact

Allison Bianchi- 503-494-7615

Sponsor

National Institute on Aging, Alzheimer's Therapeutic Research Institute, Eli Lilly and Co.

Recruitment End

12/01/2016

Compensation Provided

Yes

Compensation

$25.00 for each completed clinical study visit and $25.00 for each completed infusion visit.


Go Back